By Dr. Benjamin Caplan, MD | Board-Certified Family Physician, CMO at CED Clinic | Evidence Watch
Prescription-grade cannabidiol (Epidiolex) has solid randomized trial evidence showing meaningful seizure reduction in children with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. However, this 2025 review clarifies that evidence beyond those three syndromes remains limited, drug interactions require careful management, and artisanal CBD products lack the rigorous trial data supporting pharmaceutical formulations.
What the Evidence Really Says About CBD for Children With Epilepsy
A 2025 clinical update published in Indian Pediatrics synthesizes landmark randomized controlled trial data on cannabidiol’s efficacy, safety profile, dosing protocols, drug interactions, and monitoring requirements for its use in pediatric drug-resistant epilepsy, while drawing a clear line between pharmaceutical-grade CBD and artisanal products.
#78
Strong Clinical Relevance
Directly addresses cannabinoid prescribing decisions that clinicians and families face in pediatric epilepsy, consolidating evidence from multiple landmark trials into actionable guidance.
Pediatric Epilepsy
Drug-Resistant Seizures
Drug Interactions
Epidiolex
Drug-resistant epilepsy affects a substantial proportion of children with seizure disorders, and families frequently ask about cannabidiol as a treatment option. The regulatory approval of pharmaceutical-grade CBD has created a genuine clinical tool, but it has also generated confusion about whether over-the-counter or artisanal CBD products offer comparable benefit. Clinicians need a consolidated, evidence-grounded resource that distinguishes what has been proven in rigorous trials from what remains speculative, and that provides practical guidance on dosing, monitoring, and the real pharmacological risks of coadministration with common antiseizure medications.
Approximately one-third of children with epilepsy develop drug-resistant disease, defined as failure of two or more appropriately chosen and tolerated antiseizure medications. Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex represent particularly severe forms in which conventional treatment options are often insufficient. Cannabidiol, a non-intoxicating phytocannabinoid, has emerged as an adjunctive therapy through a mechanism of action that is incompletely understood but appears to involve modulation of GPR55, TRPV1, adenosine reuptake, and intracellular calcium signaling rather than direct CB1 or CB2 receptor agonism. Pharmaceutical-grade CBD (marketed as Epidiolex in the United States and Epidyolex in Europe) received FDA approval for patients one year and older with these three syndromes, and EMA approval for those two years and older.
The review synthesizes results from five pivotal placebo-controlled randomized trials, reporting responder rates of approximately 36 to 49 percent and median seizure reductions of roughly 39 to 49 percent in Dravet and Lennox-Gastaut syndromes. Open-label extension data suggest sustained efficacy over longer periods. Common adverse effects include somnolence, diarrhea, decreased appetite, and fatigue, with hepatotoxicity representing the most serious safety concern, necessitating structured liver enzyme monitoring at baseline and at one, three, and six months. A critical pharmacokinetic interaction with clobazam, which produces a three-fold increase in N-demethylclobazam levels, substantially raises sedation risk. The authors note that artisanal CBD-THC products showed similar observational responder rates but lacked the controlled trial evidence and compositional consistency of pharmaceutical formulations, and they call for further investigation into CBD’s role beyond the three approved indications.
This review does a good job of bringing the core evidence into one place. The RCTs behind Epidiolex are genuinely strong, and the approval pathway for LGS, Dravet, and TSC was rigorous by any standard. What the review rightly highlights, and what I want clinicians to internalize, is that this evidence applies specifically to pharmaceutical-grade CBD at defined doses with structured monitoring. The gap between that and what many families encounter at dispensaries or online is enormous. A parent who sees “CBD for seizures” on social media is not getting the same product, dose, or oversight that these trials describe.
In my practice, when families ask about CBD for epilepsy, I start with a clear conversation about what has actually been tested and what has not. For children who meet criteria for an approved indication, I work closely with their neurologist to ensure proper titration and monitoring, especially around clobazam coadministration. For families already using artisanal products, I do not dismiss their experience, but I do explain the risks of variable composition and the absence of trial-level safety data. That distinction matters more than most people realize.
This review sits at the consolidation stage of a research arc that began with preclinical work, moved through the pivotal RCTs of 2016 to 2018, and now extends into long-term open-label follow-up and real-world experience. Clinicians can be reasonably confident in the efficacy and safety profile of pharmaceutical CBD for the three approved indications, though the evidence base beyond these syndromes remains thin. The review’s framing of artisanal products is appropriately cautious, noting that observational responder rates appear broadly similar but that these data cannot establish equivalence or confirm safety given their inherent methodological limitations.
The pharmacokinetic interactions described here deserve particular clinical attention. The three-fold increase in N-demethylclobazam when CBD is coadministered means that sedation and respiratory depression risk may be substantially higher than anticipated without dose adjustment. Similarly, enzyme-inducing antiseizure medications such as phenytoin and carbamazepine can reduce CBD exposure by approximately half
